Key facts
- Senya Therapeutics’s last known valuation is $9.8M (Feb 2026).
- It has raised $3.5M; the latest was Seed Round ($550K) in Feb 2026.
- Notable investors include Innovate UK, AlbionVC, Vincent Tchenguiz, Cambridge Technology Capital Fund, Cancer Research — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Senya Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Senya Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Senya Therapeutics
Developer of biologics intended for unmet clinical needs in nephrology, oncology, ophthalmology, and other indications. The company utilizes antibody-based products against a protein target that promotes vascular destabilization and uninhibited blood-vessel formation in pathology, enabling medical staff & doctors to normalize and improve the vascularization of solid tumors with penetration and improved efficacy for small molecules, biologics, and cell therapies.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 2
- Website
- senyatx.com/
- Ownership
- Privately Held (backing)
Senya Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Senya Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Senya Therapeutics in its N-PORT filings yet. We sweep new filings monthly.